Genpharmasec promoter Rajesh Mirchumal Sadhwani acquired 50,00,000 equity shares in the open market on August 28, 2026. The transaction represents a 0.90% stake increase under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The acquisition was disclosed to BSE Limited and the company’s Board of Directors on August 31, 2026. Sadhwani, based in Dubai, executed the purchase through open market transactions, increasing his individual holding from 7,30,00,000 shares to 7,80,00,000 shares.

Promoter Group Holding

Sadhwani acts in concert with Sneha Sadhwani. While Sadhwani’s stake increased, Sneha Sadhwani’s holding remained unchanged at 9,30,01,000 shares (16.80%).

The combined promoter group holding now stands at 30.88% of the total voting capital. There were no changes in encumbrances, voting rights otherwise than by shares, or convertible securities associated with this transaction.

What the Numbers Show

The promoter group’s consolidated stake has crossed the 30% threshold, rising from 29.98% to 30.88%. This move consolidates control within the promoter circle without altering the relative weightage between the two persons acting in concert. With zero encumbrances reported on the acquired shares, the transaction reflects a clean addition to unpledged promoter holdings.

Genpharmasec Limited reported a standalone net profit of ₹156.96 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a slight increase from ₹155.92 lakh in the corresponding period of FY26. The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in Mumbai. While the standalone entity remained profitable, the group’s consolidated position turned negative, reporting a net loss of ₹17.37 lakh for the quarter, primarily driven by losses attributable to non-controlling interests.

The filing was made pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subsequently approved by the Board. Bilimoria Mehta & Co., Chartered Accountants, served as the independent auditors, issuing an unmodified review report. The audit committee reviewed the financial statements on August 11, 2026, before they were tabled before the Board.

Financial Performance Overview

On a standalone basis, revenue from operations rose significantly to ₹4,478.44 lakh in Q1FY27, up from ₹1,211.32 lakh in Q1FY26. Total income reached ₹4,575.50 lakh, supported by other income of ₹97.06 lakh. Expenses totaled ₹4,365.78 lakh, with purchase of stock-in-trade accounting for ₹4,530.97 lakh, partially offset by a decrease in inventories of ₹249.05 lakh. Profit before tax stood at ₹209.72 lakh, against a tax expense of ₹52.76 lakh.

Consolidated revenue from operations was ₹4,971.03 lakh, compared to ₹1,204.32 lakh in the previous year’s quarter. However, total expenses were higher at ₹4,982.57 lakh, leading to a profit before tax of only ₹25.77 lakh. After a total tax expense of ₹43.13 lakh, the group reported a net loss of ₹17.37 lakh. This contrasts with a consolidated net profit of ₹121.52 lakh in Q1FY26.

Segment-wise Analysis

The Pharmaceuticals segment contributed ₹4,478.44 lakh to revenue and generated a segment result (profit before tax and interest) of ₹222.41 lakh. The Manufacturing & Processing segment reported revenue of ₹271.92 lakh but incurred a segment loss of ₹125.07 lakh. The Laboratory Testing segment posted a loss of ₹29.20 lakh with no reported revenue for the quarter. Unallocable items accounted for ₹220.67 lakh in revenue and a minor loss of ₹2.45 lakh.

Total segment assets increased to ₹15,628.35 lakh from ₹13,815.34 lakh in the preceding quarter. Segment liabilities rose to ₹9,064.44 lakh from ₹7,250.86 lakh. The Pharmaceuticals segment held the largest share of assets at ₹6,918.07 lakh and liabilities at ₹3,936.34 lakh.

What the Numbers Show

A divergence exists between the standalone profitability and the consolidated loss position. While the parent company reported a stable net profit, the consolidated loss of ₹17.37 lakh was largely driven by non-controlling interests, which attributed a loss of ₹43.34 lakh to the group. This suggests that subsidiaries or joint ventures may be facing operational challenges that are not reflected in the parent company’s direct operations. Additionally, the Laboratory Testing and Manufacturing & Processing segments continued to report losses, indicating ongoing pressure in these business lines despite strong performance in Pharmaceuticals.